This announcement is a separate document:
科伦药业：关于子公司核心产品芦康沙妥珠单抗(sac-TMT)于2024年美国临床肿瘤学会年会上公布研究成果的公告
Sichuan Kelun Pharmaceutical: Announcement on the subsidiary's core product, lucan satuzumab (sAC-TMT), announcing research results at the 2024 American Society of Clinical Oncology Annual Meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.